Market Cap (In USD)
123.98 Million
Revenue (In USD)
79.2 Million
Net Income (In USD)
-133.81 Million
Avg. Volume
170.93 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.7-17.8
- PE
- -
- EPS
- -
- Beta Value
- 0.568
- ISIN
- US29251M1062
- CUSIP
- 29251M106
- CIK
- 1177648
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jay R. Luly Ph.D.
- Employee Count
- -
- Website
- https://www.enanta.com
- Ipo Date
- 2013-03-21
- Details
- Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
More Stocks
-
6626SEMITEC Corporation
6626
-
RGLDRoyal Gold, Inc.
RGLD
-
CHJTF
-
TROW
-
DV
-
300154
-
3826
-
PMNT